ERX Pharmaceuticals’ Experimental Drug Boosts Weight Loss When Combined With Semaglutide in Animal Study

0
9

CAMBRIDGE, Mass.–ERX Pharmaceuticals reported that its experimental obesity drug, ERX1000, produced substantially greater weight loss when combined with semaglutide than either treatment alone in a preclinical study involving obese mice.

The findings, presented at ObesityWeek 2026 in Washington, D.C., showed that the combination therapy achieved a placebo-adjusted body weight reduction of 36% over five weeks, compared with 18% for ERX1000 alone and 14% for semaglutide alone.

Researchers also observed improvements in muscle strength, insulin sensitivity, glucose regulation and body composition, suggesting that the combination could offer a potential approach to obesity treatment.

The results were presented November 15 by Dr. Louis Aronne, a physician at Weill Cornell Medicine’s Comprehensive Weight Control Center in New York and a member of ERX Pharmaceuticals’ Board of Directors who also chairs its Scientific Advisory Board.

ERX1000 is an investigational oral medication designed to increase the body’s sensitivity to leptin, a hormone that helps regulate appetite, energy expenditure and body weight.

Leptin signals the brain about the body’s energy reserves and helps influence hunger and metabolism. However, people with obesity frequently develop leptin resistance, a condition in which the brain becomes less responsive to the hormone’s signals.

ERX1000 is being developed to restore leptin sensitivity, potentially reducing food intake while preventing the decline in energy expenditure that often accompanies weight loss.

Semaglutide, a GLP-1 receptor agonist, is the active ingredient in Novo Nordisk’s Ozempic and Wegovy medications, which are used to treat diabetes and obesity, respectively.

The new study examined whether combining leptin sensitization with GLP-1 therapy could produce greater metabolic benefits than either treatment independently.

Researchers found that the combination reduced food intake by 39%, compared with 9% for semaglutide alone and 3% for ERX1000 alone.

The combined treatment also improved oral glucose tolerance and insulin sensitivity, reduced fat accumulation and lowered lipid levels in the bloodstream and liver.

In addition to greater weight loss, the treatment appeared to improve muscle function and body composition.

Mice receiving the combination demonstrated a 32% improvement in weight-normalized grip strength compared with placebo, while ERX1000 alone produced a 25% improvement and semaglutide alone resulted in an 8% increase.

The combination also increased lean mass and improved the ratio of lean tissue to body fat.

Researchers reported a 78% reduction in total cholesterol levels in the liver compared with placebo, along with decreases in liver fat and circulating cholesterol.

The study, conducted by Physiogenex in France, also found that the combination did not produce a decline in body-weight-adjusted energy expenditure.

“These findings support leptin sensitization as a potential strategy to enhance the metabolic efficacy of GLP-1 receptor agonist therapy in obesity,” said Aronne. “We believe this therapy could play a role in the fight against obesity moving forward.”

The findings suggest that targeting leptin resistance could complement existing GLP-1 medications by addressing biological mechanisms that make sustained weight loss difficult.

As patients lose weight, the body often responds by increasing hunger and reducing energy expenditure, creating challenges for maintaining weight reduction.

ERX Pharmaceuticals believes improving leptin sensitivity could help counteract some of these responses.

“Among other benefits, the combination therapy may mean patients can lower their GLP-1 dose and reduce accompanying side effects,” Aronne added.

However, the findings remain preliminary because the combination has been evaluated in animals rather than humans. Additional clinical studies will be needed to determine whether similar benefits can be achieved safely in patients with obesity.

Teo Uysal, CEO of ERX Pharmaceuticals, said the company’s approach focuses on restoring the body’s natural mechanisms for regulating appetite.

“Resistance to the hormone leptin interrupts proper signaling to the brain regarding how much to eat and when to stop. By overcoming leptin resistance, it appears we may be able to restore more normal regulation of appetite and other metabolic benefits.”

ERX1000 is currently undergoing a Phase 2a clinical trial as a standalone treatment for obesity. The study is evaluating its safety and tolerability in men and women with obesity.

The company previously completed two Phase 1 trials, including an initial study that demonstrated dose-dependent weight loss without serious nausea or gastrointestinal side effects during a one-month treatment period.

A second Phase 1 trial investigated a weekly dosing schedule.

“Moreover, with our Phase 2a study currently underway, we are hopeful that additional positive results regarding ERX1000 are yet to come,” Uysal said.

The Phase 2a trial is expected to conclude during the second half of 2027.

Beyond obesity, ERX1000 has received Orphan Drug Designation for Prader-Willi syndrome, a rare genetic disorder characterized by persistent and excessive hunger.

The condition can cause severe obesity and associated health complications because affected individuals often experience an inability to feel full even after eating.

ERX Pharmaceuticals is continuing development of ERX1000 as it investigates whether leptin sensitization could improve the effectiveness of existing obesity treatments and support longer-term weight management.

Leave A Reply

Please enter your comment!
Please enter your name here